Guide to the comprehensive treatment of spasticity;Guía del tratamiento integral de la espasticidad

Revista de Neurologia

Volumn 45, Issue 6, 2007, Pages 365-375

  Vivancos Matellano, Francisco ^a   Pascual Pascual, S I ^a   Nardi Vilardaga, J ^b   Miquel Rodriguez F ^b   De Miguel Leon I ^c   Martinez Garre M C ^b   Martinez Caballero I ^d   Lanzas Melendo, G ^e   Garreta Figuera, R ^f   Garcia Ruiz P J ^g   Garcia Bach M ^f   Garcia Aymerich V ^c   Bori Fortuny, I ^b   Aguilar Barbera M ^f  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c HOSPITAL UNIVERSITARIO LA FE   (Spain)

^d HOSPITAL INFANTIL UNIVERSITARIO NIÑO JESÚS   (Spain)

^e HOSPITAL CENTRAL DE LA DEFENSA GÓMEZ ULLA   (Spain)

^f HOSPITAL MÚTUA DE TERRASSA   (Spain)

^g Hospital UniversitarioFundación Jiménez Díaz   (Spain)

Author keywords

Comprehensive treatment; Multidisciplinary team; Pathophysiology; Spasticity; Treatment guide; Upper motoneuron syndrome

Indexed keywords

BACLOFEN; BOTULINUM TOXIN; CLONIDINE; DANTROLENE; DIAZEPAM; GABAPENTIN; TIZANIDINE; CENTRAL MUSCLE RELAXANT; MUSCLE RELAXANT AGENT;

BODY POSTURE; CAREGIVER; CEREBRAL PALSY; DISEASE COURSE; ELASTICITY; FUNCTIONAL DISEASE; GENERAL PRACTITIONER; HUMAN; INCIDENCE; JOINT FUNCTION; MOTOR NEURON DISEASE; OCCUPATIONAL THERAPIST; ORTHOPEDIC SURGERY; PAIN; PHYSIOTHERAPY; PLASTICITY; REVIEW; SOFT TISSUE; SPASTICITY; SPINAL CORD INJURY; STROKE; SURGEON; TRAUMATIC BRAIN INJURY; VISCOSITY; ARTICLE; PATHOPHYSIOLOGY; PRACTICE GUIDELINE;

BACLOFEN; CEREBRAL PALSY; DISEASE PROGRESSION; HUMANS; MUSCLE RELAXANTS, CENTRAL; MUSCLE SPASTICITY; NEUROMUSCULAR AGENTS; PHYSICAL THERAPY MODALITIES;

EID: 37349018686     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.4506.2007239     Document Type: Review

References (77)

1. Aguilar-Barberá M, Bori-Fortuny I, García-Aymerich V, García-Ruiz Espiga PJ, Garreta-Figuera R, Herrera-Galante, et al. Guía terapéutica de la espasticidad del adulto con toxina botulínica. Rev Neurol 2004; 38: 971-8.
2. Pascual-Pascual SI, Herrera-Galante A, Poó P, García- Aymerich V, Aguilar-Barberá M, Bori-Fortuny I, et al. Guía terapéutica de la espasticidad infantil con toxina botulínica. Rev Neurol 2007; 44: 303-9.
3. Young R, Delwaide P. Drug therapy, spasticity. N Engl J Med 1981; 304: 28-33.
4. Brown P. Pathophysiology of spasticity. J Neurol Neurosurg Psychiatry 1994; 57: 773-7.
5. Gracies JM. Pathophysiology of spastic paresis. I: paresis and soft tissue changes. Muscle Nerve 2005; 31: 535-51.
6. Thompson PD. Rigidity and spasticity. In Jankovic J, Tolosa E, eds. Parkinson's disease and movement disorders. Baltimore: Williams & Wilkins; 1998. p. 755-62.
7. Fahn S. Generalized dystonia: concept and treatment. Clin Neuropharmacol 1986; 9 (Suppl 2): S37-48.
8. Sheean G. Neurophysiology of spasticity. In Barnes MP, Jonson GR, eds. Cambridge: Cambridge University Press; 2001. p. 12-78.
9. Lance JW. Symposium sinopsis. In Feldman RG, Young RR, Koella WP, eds. Spasticity: disorder of motor control. Chicago: Year Book Medical Publishers; 1980. p. 485-94.
10. Lance JW. Piramidal and extrapyramidal disorders. In Shahani BT, ed. Electromyography in CNS disorders: central EMG. Boston: Butterworth; 1984. p. 1-19.
11. Mayer H, Esquenazi A, Childers M. Common patterns of clinical motor dysfunction. In Mayer MH, Simpson DM, eds. Spasticity: etiology, evaluation, management and the role of botulinum toxin. New York: We Move; 2002. p. 16-26.
12. Mayer N. Clinicophysiologic concepts of spasticity and motor dysfunction in adults with an upper motoneurona lesion. In Mayer MH, Simpson DM, eds. Spasticity: etiology, evaluation, management and the role of botulinum toxin. New York:We Move; 2002. p. 1-10.
13. Adams MM, Hicks AL. Spasticity after spinal cord injury. Spinal Cord 2005; 43: 577-86.
14. Sköld C, Levi R, Seiger AKE. Spasticity after traumatic spinal cord injury: nature severity, and location. Arch Phys Med Rehabil 1999; 80: 1548-57.
15. Sewmon DA. Spinal shock and brain death: somatic pathophysiological equivalence and implications for the integrative unity rationale. Spinal Cord 1999; 37: 313-24.
16. Deleaide PJ. Spasticité. Rencontres autour du blesse médullaire. Paris: Masson; 1990. p. 37-44.
17. Ditunno JF. Functional assessment in CNS Trauma. J Neurotrauma 1992; 9: 5301-5.
18. Ditunno JF, Young W, Donovan WH, Creasey G. The international standards booklet for neurological and functional classification of spinal cord injury. Paraplegia 1994; 32: 70-80.
19. Maynard FM Jr, Braken MB, Creasey G, Ditunno JF Jr, Donovan WH, Ducker TB, et al. International standards for neurological and functional classification of spinal cord injury. Spinal Cord 1997; 35: 266-74.
20. Giner M, Delgado M, Miguel I, Forner V, Miró R. Guía de autocuidados de la lesión medular. 2 ed. Valencia: Generalitat Valenciana; 2001.
21. Bax MCO. Terminology and classification of cerebral palsy. Dev Med Child Neurol 1964; 6: 295-307.
22. Aicardi J, Bax M. Cerebral palsy. In Aicardi J, ed. Diseases of the central nervous system in childhood. London: MacKeith Press; 1998. p. 210-39.
23. Stanley E, Blair E, Alberman E. How common are the cerebral palsies? In Stanley E, Blair E, Alberman E. Cerebral palsies: epidemiology and causal pathways. London: MacKeith Press; 2000. p. 22-39.
24. Bax M, Goldstein M, Rosenbaum P, Leviton A, Paneth N, Dan B, et al, Executive Committee for the Definition of Cerebral Palsy. Proposed definition and classification of cerebral palsy, april 2005. Dev Med Child Neurol 2005; 47: 571-6.
25. Palisano R, Rosenbaum P, Walter S, Russell D, Wood E, Galuppi B. Development and reliability of a system to classify gross motor function in children with cerebral palsy. Dev Med Child Neurol 1997; 39: 214-23.
26. Graham HK. Classifying cerebral palsy. J Pediatr Orthop 2005; 25: 127-8.
27. Ashwal S, Russman BS, Blasco PA, Miller G, Sandler A, Shevell M, et al. R Practice parameter: diagnostic assessment of the child with cerebral palsy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 2004; 62: 851-63.
28. Johnson DC, Damiano DL, Abel MF. The evolution of gait in childhood and adolescent cerebral palsy. J Pediatr Orthop 1997; 17: 392-6.
29. De Souza LH, Langton-Hewer R, Miller S. Assessment of recovery of arm control in hemiplegic stroke patients. I. Arm function test. Int Rehabil Med 1980; 2: 3-9.
30. Verplancke D, Salisbury CF, Snape S, Jones PW, Ward AB. A comparative randomised controlled trial of the management of early lower limb spasticity following acute acquired severe brain injury. Clin Rehabil 2005; 19: 117-25.
31. Herring J. Disorders of the brain. In Herring J, ed. Tachdjian's pediatric orthopaedics. Chicago: Saunders; 2002. p. 1122-242.
32. Miller F. Cerebral palsy. New York: Springer-Verlag; 2005.
33. Renshaw T, Green N, Griffin P, Root L. Cerebral palsy: orthopaedic management. Instr Course Lect 1996; 45: 475-90.
34. Munuera L. Fisiopatología del aparato de crecimiento. En Munuera L, ed. Introducción a la traumatología y cirugía ortopédica. Mexico: Mc-Graw-Hill/Interamericana; 1997. p. 118-31.
35. Emery D, Wedge J. Orthopaedic management of children with total body involvement cerebral palsy. Mini symposium: cerebral palsy. Curr Orthop 2003; 17: 81-7.
36. Knapp Jr, Cortes H, Untreated hip dislocation in cerebral palsy. J Pediatr Orthop 2002; 22: 668-71.
37. Guerra-Romero L. La medicina basada en la evidencia: un intento de acercar la ciencia al arte de la práctica clínica. Med Clin (Barc) 1996; 107: 377-82.
38. Guyatt GH, Sackett DL, Sinclair JC, Hayward R, Cook DJ, Cook RJ. User's guides to the medical literature: IX. A method for grading health care recommendations. JAMA 1995; 274: 1800-4.
39. Center for Evidence-Based Medicine. URL: http://www.cebm.net/ levels_of_evidence.asp. [17.07.2007].
40. Remy-Néris O, Denys P, Azouvi A, Jouffroy S, Fairre S, Laurans A, et al. Kinesiterapia: espasticidad. Enciclopedia Médico-Quirurgica. Elsevier, 2003.
41. Gazzani F, Bernardi M, Macaluso A, Coratella D, Ditunno JF Jr, Castellano V, et al. Ambulation training of neurological patient on the treadmill with a new walking Assistance and Rehabilitation Device (WARD). Spinal Cord 1999; 37; 336-44.
42. Denys P. Spasticity and spinal cord injury. II Congreso de la Sociedad Española de Neurorrehabilitación. Mesa redonda: Abordaje y tratamiento de la espasticidad. Barcelona; 2002.
43. Asch PV. Spasticity and Physiotherapy. II Congreso de la Sociedad Española de Neurorrehabilitación. Mesa redonda: Abordaje y tratamiento de la espasticidad. Barcelona; 2002.
44. Watanabe T. The role of therapy in spasticity management. Am J Phys Med Rehabil 2004; 83 (Suppl): S45-9.
45. Dawson DM. Evidence basis for treatment of spasticity. Curr Neurol Neurosci Rep 2001; 1: 501-6.
46. Young R, Delwaide P. Drug therapy, spasticity. N Engl J Med 1981; 304: 28-33.
47. Brin MF, Aoki R. Botulinum toxin type A: pharmacology. In Mayer MH, Simpson DM, eds. Spasticity: etiology, evaluation, management and the role of botulinum toxin. New York:We Move; 2002. p. 110-24.
48. Guillaume D, Van Havenbergh A, Vloeberghs M, Vidal J, Roeste G. A clinical study of intrathecal baclofen using a programmable pump for intractable spasticity. Arch Phys Med Rehabil 2005; 86: 2165-71.
49. Vidal J, Fenollosa P, Martín E, Barberá J, Robaina FJ, Fuentes M, et al. Safety and efficacy of intrathecal baclofen infusion by implantable pump for the treatment of severe spinal spasticity: a Spanish Multicenter Study. Neuromodulation 2000; 3: 175-82.
50. Ordia JI, Fischer E, Adamski E, Chagnon KG, Spatz EL. Continuous intrathecal baclofen infusion by a programmable pupa in 131 consecutive patients with severe spasticity of spinal origin. Neuromodulation 2002; 5: 16-24.
51. Ben Smail D, Peskine A, Roche N, Mailhan L Thiébaud JB, Bussel B, et al. Intrathecal baclofen for treatment of spasticity of multiple sclerosis patients. Mult Scler 2006; 12: 101-3.
52. Ochs G, Naumann C, Dimitrijevic M, Sindou M. Intrathecal baclofen therapy for spinal origin spasticity: spinal cord injury, spinal cord disease, and multiple sclerosis. Neuromodulation 1999; 2: 108-19.
53. Loubser PG, Narayan RK, Sandin KJ, Donovan WH, Russell KD. Continuous infusion of intrathecal baclofen: long-term effects on spasticity in spinal cord injury. Paraplegia 1991; 29: 48-64.
54. Coffey R, Cahill D, Steers W, Park TS, Ordia J, Meythaler J, et al. Intrathecal baclofen for intractable spasticity of spinal origin: results of a long-term multicenter study. J Neurosurg 1993; 78: 226-32.
55. Becker R, Alberti O, Bauer BL. Continuous intrathecal baclofen infusion in severe spasticity after traumatic or hypoxic brain injury. J Neurol 1997; 244: 160-6.
56. Armstrong RW, Steinbok P, Cochrane D, Kube SD, Fife SE, Farrell K. Intrathecally administered baclofen for treatment of children with spasticity of cerebral origin. J Neurosurg 1997; 87: 409-14.
57. Gerszten P, Albright L, Johnstone G. Intrathecal baclofen infusion and subsequent orthopaedic surgery in patients with spastic cerebral palsy. J Neurosurg 1998; 88: 1009-13.
58. Becker WJ, Harris CJ, Long ML, Abblett DP, Klein GM, DeForge DS. Long-term intrathecal baclofen therapy in patients with intractable spasticity. Can J Neurol Sci 1995; 22: 208-17.
59. Dario A, Scamoni C, Picano M, Casagrande F, Tomei G. Pharmacological complications of the chronic baclofen infusion in the severe spinal spasticity. Personal experience and review of the literature. J Neurosurg Sci 2004; 48: 177-81.
60. Bache C, Selber P, Graham H. The management of spastic diplegia. Mini symposium: cerebral palsy. Curr Orthop 2003; 7: 88-104.
61. Molenaers G, Desloovre J, De Cat I. Single event multilevel botulinum toxin type A treatment and surgery similarities and differences. Eur J Neurol 2001; 8 (Suppl 5): S88-97.
62. Foerster O. On the indications and results of the scission of the posterior spinal nerve roots in men. Surg Gynecol Obstet 1913; 16: 463-74.
63. Sindou M, Fischer G, Goutelle A, Schott B, Mansuy L. La radicellotomie postérieure sélective dans le traitement des spasticités. Rev Neurol (Paris) 1974; 130: 201-15.
64. Siegfried J. Treatment of spasticity by dorsal cord stimulation. Int Rehabil Med 1980; 2: 31-4.
65. Barolat-Romana G, Myklebust JB, Hemmy DC, Myklebust B, Wenninger W. Immediate effects of spinal cord stimulation in spinal spasticity. J Neurosurg 1985; 62: 558-62.
66. Richardson RR, McLone DG. Percutaneous epidural neurostimulation for paraplegic spasticity. Surg Neurol 1978; 9: 153-5.
67. Bonita R. Epidemiology of stroke. Lancet 1992; 339: 342-4.
68. Thorvaldsen P, Asplund K, Kuulasmaa K, Rajakangas AM, Schroll M. Stroke incidence, case fatality, and mortality in the WHO MONICA project. Stroke 1995; 26: 361-7.
69. Sommerfeld DK, Eek EU, Svensson AK, Holmqvist LW, Von Arbin MH. Spasticity after stroke: its occurrence and association with motor impairments and activity limitations. Stroke 2004; 35: 134-9.
70. Welmer AK, Von Arbin M, Holmqvist LW, Sommerfeld DK. Spasticity and its association with functioning and health-related quality of life 18 months after stroke. Cerebrovasc Dis 2006; 21: 247-53.
71. Watkins CL, Leathley MJ, Gregson JM, Moore AP, Smith TL, Sharma AK. Prevalence of spasticity post stroke. Clin Rehabil 2002; 16: 515-22.
72. Singer A, Hollander J, Quinn J. Evaluation and management of traumatic lacerations. N Engl J Med 1997; 337: 1142-8.
73. García-Reneses J, Herruzo R. Epidemiología descriptiva de la prevalencia de la lesión medular espinal en España. Médula Espinal 1995; 1: 111-5.
74. Mazaira-Álvarez J. Epidemiología de la lesión medular de 8 comunidades autónomas 1974-1993. Medula Espinal 1997; 3: 28-57.
75. Rizzo M, Hadjimichael O, Preiningerova J, Vollmer T. Prevalence and treatment of spasticity reported by multiple sclerosis patients. Mult Scler 2004; 10: 589-85.
76. Johnson A. Prevalence and characteristics of children with cerebral palsy in Europe. Dev Med Neurol 44: 633-40.
77. Krageloh-Mann I, Hagberg G, Meisner C, Schelp B, Haas G, Eeg-Olofsson K, et al. Bilateral spastic cerebral palsy -a comparative study between southwest Germany and western Sweden. II: Epidemiology. Dev Med Child Neurol 1994; 36: 473-83.